The MPS2 test was approved for Medicare coverage in September 2024.

“The coverage determination means that patients meeting the policy criteria—those at risk for prostate cancer and candidates for either an initial or repeat biopsy—will now have access to MPS2 under their Medicare plans.”
https://www.lynxdx.com/2024/11/news/my-prostate-score-medicare-coverage/